We are a clinical-stage biopharmaceutical company with deep virology expertise and an unwavering focus on curing conditions with unmet medical need. Today, we’re drawing upon our understanding and expertise in treating viral infections with our novel therapeutics focused on hepatitis B virus (HBV).
President & CEO and Chairperson
Chief Financial Officer
General Counsel
Imdusiran is a subcutaneously-delivered RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral antigens, including hepatitis B surface antigen (HBsAg), which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus. Imdusiran targets hepatocytes using our novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology.
The immune system of HBV chronically infected patients is tolerized to recognize the virus or infected cells. To achieve a functional cure and long-term HBV viral control, it is believed that highly functional HBV specific T-cells are required.
Immune checkpoints such as PD-1/PD-L1 play an important role in the induction and maintenance of immune tolerance and in T-cell activation.
WARMINSTER, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that three abstracts featuring imdusiran data and one abstract featuring AB-101 data, have been accepted for poster presentations at the American Association for the Study of Liver Diseases (“AASLD”) – The Liver Meeting 2025, taking place November 7–11 in Washington, DC. Notably, the AB-101 abstract has been selected as a Poster of Distinction.
Recruiting Done Differently.
Improving lives by uniting great people with great companies.
We’re committed to sharing up-to-date industry insights, our newest career opportunities, and valuable tools to support you throughout your next job search. Let’s stay connected!